Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
July 10, 2010
Is carbo/doxil non-inferior to carbo/paclitaxel in women with platinum sensitive recurrent ovarian cancer?
Carboplatin AUC 5 + paclitaxel 175 mg/m2
q3 weeks x6 cycles
Carboplatin AUC 5 + Pegylated Liposomal Doxirubicin 30 mg/m2
q4 weeks x6 cycles
PFS
Measurable ovarian cancer
Recurrence >6months after first or second line platinum with taxane
Pre-existing neuropathy or cardiomyopathy
carbo/doxil vs carbo/taxol:
median f/u: 22 mos
PFS: 11.3 vs 9.4 mos (SS)
Neutropenia (G3/G4): 35% vs 45% (SS)
Thrombocytopenia (G3/G4): 15.9% vs 6.2% (SS)
Anemia (G3/G4): 7.9% vs 5.4% (NS)
Alopecia (≥G2): 7% vs 83.6% (SS)
Nausea/Vomiting: 22-35% vs 15-24% (SS)
Carbo/Doxil is non-inferior to Carbo/Taxol in recurrent platinum-sensitive ovarian cancer with a favorable side effect profile